Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
Completed
- Conditions
- Hormon Receptor Positive Breast Cancer
- Registration Number
- NCT01208779
- Lead Sponsor
- AstraZeneca
- Brief Summary
This observational study in estrogen receptor positive early breast cancer patients is aimed to evaluate the patients' compliance to aromatase inhibitor (AI) therapy and to collect country-specific data in estrogen receptor positive early breast cancer patients including data on demography, disease characteristics and disease management.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 90
Inclusion Criteria
- Postmenopausal females with estrogen receptor positive breast cancer that are currently treated with aromatase inhibitor (AI) medication
- Provision of subject informed consent
Exclusion Criteria
- If participating in any clinical trial, the subject cannot take part in this study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluate compliance rate, as assessed by investigator, after 12 months from baseline. 12 months
- Secondary Outcome Measures
Name Time Method Evaluate compliance rate, assessed by investigator, after 6 months of follow up 12 months Evaluate the extent of patient educational activities as assessed by patient (using patient questionnaire) after 6 and 12 months 12 months Evaluate patient compliance as assessed by the patient (using patient questionnaire) after 6 and 12 months 12 months Collect epidemiology data; Demographic data: age, height, weight, lifestyle, menarche, childbirth, lactation, menopausal status 12 months Primary disease (breast cancer) characteristics: receptor status, disease stage 12 months Disease management data: treatment/treatment changes 12 months
Trial Locations
- Locations (1)
Research Site
🇷🇸Belgrade, Serbia